BMS-345541 Hydrochloride: Selective IKK Inhibitor for NF-κB Pathway Research

Executive Summary: BMS-345541 hydrochloride is a potent, highly selective inhibitor of IκB kinase isoforms IKK-1 and IKK-2, with respective IC₅₀ values of 4 μM and 0.3 μM, and minimal activity against other kinases (APExBIO). It blocks the NF-κB pathway by binding allosterically to IKK and suppressing pro-inflammatory cytokine transcription such as TNFα, IL-1β, IL-6, and IL-8 in vitro and in vivo (Du et al., 2021). The compound induces apoptosis and G2/M cell cycle arrest in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, indicating its utility in chemoresistance studies. BMS-345541 hydrochloride exhibits >60 mg/mL solubility in water and achieves 100% oral bioavailability in animal models. It is recommended for -20°C storage, with stable stock solutions for several months under these conditions (APExBIO).

Biological Rationale

The IKK/NF-κB signaling axis is a central regulator of immune response, cell survival, and inflammation (Du et al., 2021). Upon stimulation by inflammatory cytokines like TNFα, the IKK complex phosphorylates IκB proteins, leading to their degradation and subsequent nuclear translocation of NF-κB transcription factors. This triggers the transcription of genes involved in inflammation, immune modulation, and cell survival. Dysregulation of this pathway is implicated in chronic inflammatory diseases and various cancers, including T-cell acute lymphoblastic leukemia (T-ALL). Selective inhibition of IKK, particularly IKK-1 and IKK-2, is therefore pivotal for modulating NF-κB-driven pathology. BMS-345541 hydrochloride, developed and distributed by APExBIO, provides a molecular tool for dissecting these processes with high specificity (APExBIO).

Mechanism of Action of BMS-345541 hydrochloride

BMS-345541 hydrochloride exerts its effect by binding to an allosteric site on the IKK enzyme complex, primarily inhibiting the catalytic activity of IKK-2 (IC₅₀ = 0.3 μM) and, to a lesser extent, IKK-1 (IC₅₀ = 4 μM). This binding prevents the phosphorylation of IκB proteins, thereby blocking the release and nuclear translocation of NF-κB transcription factors (Du et al., 2021). As a consequence, transcription of NF-κB-dependent pro-inflammatory cytokines (TNFα, IL-1β, IL-6, IL-8) is suppressed. Notably, BMS-345541 does not inhibit other protein kinases, including serine/threonine and tyrosine kinases, which underscores its selectivity (APExBIO).

The inhibition is reversible and does not affect basal phosphorylation states of unrelated signaling proteins, reducing off-target effects. This specificity makes BMS-345541 hydrochloride a valuable tool for delineating canonical and non-canonical NF-κB pathway activity in diverse cellular models (see this analysis for allosteric mechanism contrasts).

Evidence & Benchmarks

• BMS-345541 hydrochloride inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM under in vitro kinase assay conditions (25°C, pH 7.5) (APExBIO).
• NF-κB-dependent transcription of TNFα, IL-1β, IL-6, and IL-8 is suppressed in both cell-based and animal models following BMS-345541 treatment (Du et al., 2021).
• BMS-345541 does not inhibit non-IKK kinases, as confirmed by kinase panel screening at 10 μM in cell lysates (APExBIO).
• Induces apoptosis and G2/M phase cell cycle arrest in T-ALL cell lines at concentrations ≥1 μM, with observed increases in apoptotic markers (Annexin V+, caspase-3 activation) after 24–72 h incubation (Du et al., 2021).
• Demonstrates 100% oral bioavailability and robust systemic inhibition of TNFα production in rodent models (dosage: 10 mg/kg, oral gavage, 2 h post-administration) (APExBIO).

These benchmarks distinguish BMS-345541 hydrochloride from earlier-generation IKK inhibitors. For a comprehensive strategic outlook on IKK/NF-κB targeting, see this strategic guidance article, which this article extends by providing up-to-date quantitative parameters and workflow integration details.

Applications, Limits & Misconceptions

BMS-345541 hydrochloride is widely used in:

• Dissecting NF-κB pathway signaling in inflammation, immunity, and cancer biology research.
• Validating the role of IKK in the regulation of pro-inflammatory cytokines and apoptosis.
• Modeling chemoresistance and apoptosis in T-ALL and other cancer cell lines (see this article for distinct T-ALL insights).
• Evaluating the effect of selective NF-κB inhibition in disease models, including animal studies with oral administration.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: BMS-345541 hydrochloride is selective for IKK-1/2 and does not inhibit unrelated kinases at standard research concentrations.
• Limited effect on non-canonical NF-κB signaling: The compound predominantly blocks canonical, IKK2-driven NF-κB activation.
• Solubility limitations: It is insoluble in DMSO and ethanol; solutions should be prepared in water only for biological assays.
• Storage stability: Repeated freeze-thaw cycles or prolonged room temperature exposure may degrade the compound—stock solutions must be stored at -20°C and used promptly after thawing.
• Not a direct RIPK1 inhibitor: BMS-345541 does not directly inhibit RIPK1 or modulate necroptosis unless mediated through NF-κB-dependent mechanisms (Du et al., 2021).

This article updates the detailed workflow parameters and selectivity insights discussed in recent application reviews, with a focus on solution handling and bioavailability.

Workflow Integration & Parameters

• Solubility: Dissolve BMS-345541 hydrochloride in water at concentrations up to ≥60 mg/mL. Do not use DMSO or ethanol as solvents (APExBIO).
• Storage: Store powder and solutions at -20°C. Avoid repeated freeze-thaw cycles. Use freshly prepared solutions for most consistent results.
• Stock Stability: Aqueous stock solutions remain stable for several months at -20°C. Do not store working solutions at room temperature for extended periods.
• In vitro use: Typical working concentrations range from 0.1 μM to 10 μM, depending on target cell type and experimental design.
• In vivo dosing: Oral administration of 10 mg/kg in rodent models achieves complete systemic inhibition of TNFα production within 2 hours post-dose.

For advanced experimental strategies and differentiation among IKK inhibitors, consult this integration guide, which this dossier updates with newly quantified stability and selectivity benchmarks.

Conclusion & Outlook

BMS-345541 hydrochloride, as provided by APExBIO, remains a gold-standard tool for selective inhibition of the IKK/NF-κB pathway in inflammation, apoptosis, and cancer research. Its quantitative selectivity, robust in vivo bioavailability, and validated workflow parameters facilitate reproducible, mechanistic studies. While not a panacea for all NF-κB-related models—particularly involving non-canonical pathway or RIPK1-independent apoptosis—its integration into research pipelines enables precise dissection of canonical pathway functions. Ongoing developments in IKK/NF-κB biology and cell death regulation further highlight the utility of BMS-345541 hydrochloride for next-generation disease modeling and therapeutic innovation.